To determine the incidence and predictors of, and effects of fenofibrate on silent myocardial infarction (MI) in a large contemporary cohort of patients with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Introduction
Most patients with a myocardial infarction (MI) have significant symptoms and present to hospital for treatment. Some, however, have an asymptomatic MI that is identified later when an electrocardiogram (ECG) shows the presence of Q waves. The reported proportion of silent MIs ranges from 22 to 40%. 1 Although patients with diabetes are at greater risk of MI, the proportion of silent MIs may be similar to that in the general population. 2 One community-based observational study reported that the risk of cardiac death in type 2 diabetes was lower with silent MI than overt coronary heart disease, 3 but active screening studies have shown that unrecognized myocardial ischaemia has a relatively poor prognosis. 4, 5 Estimates of prevalence of silent MI in type 2 diabetes vary, depending on the source populations and inclusion criteria such as sex, age, diabetes duration, and the presence of diabetic, cardiovascular, or renal complications. Also, there is no standard definition for the diagnosis of silent MI. Various methods of testing for silent MI, such as resting electrocardiography, thallium scintigraphy, and coronary angiography, 2,3,5 -15 have been used, complicating direct comparisons between studies. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial was the largest clinical-endpoint trial of lipidmodifying therapy in type 2 diabetes. 16 We reported that fenofibrate significantly reduced non-fatal clinical MI events (which by definition excluded silent MI) by 24% [fenofibrate 158 (3%) vs. placebo group 207 (4%); hazard ratio (HR) 0.76, 95% confidence interval (CI) 0.62-0.94; P ¼ 0.01].
We have now determined the proportion of silent first MIs on the basis of resting ECG readings taken routinely throughout the study and assessed their relationships with potential baseline risk factors and subsequent clinical cardiovascular disease (CVD) events. We also investigated whether fenofibrate prevented silent MI.
Methods Patients
A total of 9795 patients with type 2 diabetes, aged 50 -75 years, were recruited to the FIELD study and randomized to fenofibrate 200 mg daily or matching placebo. 16 Patients had total cholesterol 3.0 -6.5 mmol/L plus total-to-HDL cholesterol ratio over 4.0 or triglyceride 1.0-5.0 mmol/L. Patients were excluded if they had had a clinical MI within 3 months before study entry or if their physician felt that there was a clear indication for cholesterol-lowering medication. Clinical events and safety outcomes were monitored every 4 -6 months over an average of 5 years of follow-up.
Electrocardiogram collection and reading
Electrocardiograms were routinely done at baseline, 2 years, 5 years, and study close. Standard 12-lead ECGs were obtained with the patient supine at rest and forwarded to the coordinating centre in Sydney for blinded adjudication. Electrocardiograms were recorded with a calibration mark in millivolts and paper speed was marked on each trace, against which standardized measurements could be made. All ECGs were read by medical practitioners who had received training in ECG reading according to the Minnesota ECG code 17 and were unaware of patients' study treatment allocation or clinical outcome.
Definitions of Q waves and silent myocardial infarction
A diagnosis of clinical MI during the study required at least two of three criteria: ECG changes, ischaemic symptoms suggestive of myocardial ischaemic chest pain, and raised cardiac enzymes. 16 Q waves were defined as present when duration exceeded 0.03 s and they were in at least two ECG leads in the same lead group and in the absence of left bundle branch block or ventricular pacing. They were defined as new if absent from baseline or previous ECGs and as diagnostic of silent MI in the absence of a preceding clinical history of MI or unstable angina during study follow-up. All ECGs were reviewed by one reporter, and those with possible Q waves plus a random 10% of all other ECGs were reviewed by a second reporter. In the absence of concordance, a third (cardiologist) reporter adjudicated.
Endpoints
The main aims of the study were to determine: (i) the proportion of new MIs that were silent; (ii) the prognostic significance of silent MI; (iii) the effects of fenofibrate on the occurrence of silent MI and subsequent clinical outcomes; and (iv) the baseline risk factors for silent compared with clinical MI.
Statistical analyses
Analysis of differences for baseline characteristics used x 2 tests for binary variables and ANOVA for continuous variables. All continuous variables were tested for normality, and if the distribution of the data was not normal, the Kruskal -Wallis test was used. Cox proportionalhazards analysis was used to compute HRs to assess the effect of fenofibrate treatment on the time to first event. P-values were computed from the log-rank test for all non-MI outcomes. Cumulative incidence curves of the time to first event, and by treatment group, used the Kaplan -Meier method. Landmark analysis was used to analyse events after a silent MI, 18 which could be detected only at 2 or 5 years after randomization or at study close, when routine ECGs were done; using the 2 year time point ensured an average of at least 3 years of follow-up thereafter. For outcomes measured at intervals (silent MI and all composite outcomes that included silent MI), interval-censored proportional-hazards methods were used. 19 All statistical inferences used two-sided P ¼ 0.05, with no adjustment for multiple comparisons. 20 All analyses were by intention-to-treat and used SAS (version 9.1) or ACCORD (Analysis of Censored and Correlated Data; version 1.6.3, 2008) .
Results

Incidence of silent myocardial infarction
A total of 31 190 ECGs were retrieved and adjudicated, from over 92% of patients at each time point (Figures 1 and 2 ; Table 1 ). Concordance between two readers in reporting Q waves exceeded 92% (Cohen's kappa 0.74). New Q waves Reasons for no ECGs: patient deceased, withdrawn consent, lost to follow-up, permanent discontinuation, and other reasons for not attending for a clinic visit. P, placebo group; F, fenofibrate group. Silent MI in type 2 diabetes reflecting silent MI were found in 265 patients (2.7% of all participants). In contrast, 406 patients developed clinical MI during follow-up (4.1%), 45 (11.1% fatal), and 94 (23.2%) developed new Q waves with their first clinical MI. Of all MIs, 36.8% were silent ( Table 2 ). The distributions of territories for silent and clinical Q-wave MIs were not significantly different, with a slightly higher proportion of inferior (and fewer anterior) infarcts among silent events ( Table 3) .
Characteristics of patients with silent and clinical myocardial infarction
The baseline characteristics of those who had an on-study MI differed strikingly from those with no MI ( Table 4 ). The prevalence of standard coronary risk factors and indicators of diabetic microvascular disease were highest in those with clinical MI, intermediate with silent MI, and lowest among those without MI (Table 4) . Thus, 30.6, 26.1, and 21.0%, respectively, of these groups had microalbuminuria. Similarly, 42.8, 32.2, and 20.6% of these groups, respectively, had prior clinical CVD.
Risk factors for silent and clinical myocardial infarction
No measured characteristics significantly predicted greater odds of having a silent rather than a clinical MI. In a multivariate analysis, microalbuminuria and macroalbuminuria were somewhat stronger baseline predictors for silent than for clinical MI, but this did not reach statistical significance ( Table 5 ). The estimated likelihood of silent MI appeared to fall (about 3% per annum) with duration of diabetes, but there was no significant heterogeneity between silent and clinical MI. Predictors such as male sex, older age, prior CVD, higher haemoglobin A 1c , elevated serum creatinine, and insulin use showed a lower estimated strength of association for silent MI than for clinical MI when compared with no MI, but these differences between clinical and silent MI were not statistically significant.
Effects of fenofibrate on myocardial infarction and cardiovascular disease
Clinical non-fatal MIs were reduced by 24% in the group taking fenofibrate, and there was a non-significant reduction of 16% in silent MI (Figure 3) . Non-fatal MIs were reduced significantly by 20%. Total MIs (including fatal) were also reduced by 19%. Therefore, the number of patients needed to be treated (NNT) with fenofibrate to avoid one or more MIs over 5 years of therapy was 70. Total clinical CVD events (the first of non-fatal MI, stroke, CVD death, or coronary or carotid revascularization) were reduced by 11%, and when combined with silent MI, by 10%, an NNT of 67. After a first clinical or silent MI by the end of year 2, fenofibrate reduced further clinical CVD events by 25%, and by 78% after a silent MI. 
Prognosis after a silent or a clinical myocardial infarction
When all survivors at 2 years were classified according to having had an on-study MI, or no MI, subjects without MI had the lowest risk of future clinical CVD events. In the placebo group, the risk of CVD events in patients with silent MI (HR 4.55, 95% CI 2.90 -7.13, P , 0.001) was similar to the risk in those with clinical MI (HR 4.51, 95% CI 3.08-6.61, P , 0.001), compared with those with no MI ( Figure 4A ). The absolute risks of further CVD events over 3 years among placebo patients were 33.7% for silent MI, 28.8% for clinical MI, and 8.3% for no MI. Among patients allocated to fenofibrate, those who had a clinical MI were at the highest risk of further CVD events ( Figure 4B ). In contrast, the risks of those who had a silent MI and those who had no MI were not statistically different (HR 1.08, 95% CI 0.40 -2.89; P ¼ 0.88). Those who had a clinical MI were at a significantly higher risk of CVD events than those who had a silent MI (HR 5.76, 95% CI 2.01-16.50; P ¼ 0.001). The absolute risks of further CVD events over 3 years were 9.1% for silent MI, 39.4% for clinical MI, and 7.6% for no MI (with fewer fenofibrate-allocated subjects having had either a silent or clinical MI at 2 years Figure 4B ).
Mortality also differed significantly by MI status: coronary heart disease mortality (placebo group) was 8.6% for those with silent MI, 10.1% for clinical MI, and 1.2% for no MI (P , 0.001). Among placebo-treated subjects, all-cause mortality was 13.8% for those with silent MI, 15.2% for clinical MI, and 4.8% for no MI (P , 0.001). The same mortality patterns according to MI status were seen among the fenofibrate subjects, though there were no statistical differences in mortality between treatment arms overall or by MI status. Normal albumin/creatinine ratio was ,2.5 for men and ,3.5 for women; microalbuminuria was 2.5 for men and 3.5 for women, and macroalbuminuria was .25.0 for men and .35.0 for women.
Discussion
There was a low incidence of silent (2.7%) and clinical (4.1%) MI in this cohort over 5 years (with silent MIs making up 36.8% of all MIs), reflecting the low risk of the population recruited into the FIELD study. The Fremantle Diabetes Study of 1269 patients detected silent MI in 3.9% of patients, 43.9% of all MIs. 3 The lower rates in the FIELD study may be due to a lower baseline risk profile or greater use of cardiovascular therapies, but the proportion of MIs that were silent remained high. Most predictors of clinical MI also predicted silent MI, although the associations appeared more modest for silent events. Overall, the silent MI group had an intermediate risk profile between the no MI and clinical MI groups. Microalbuminuria is associated with silent coronary artery disease in people with type 1 21 and type 2 22 diabetes. It has been suggested that in patients over 60 years of age with type 1 or type 2 diabetes, autonomic neuropathy and other cardiovascular risk factors, such as development of microalbuminuria, should be screened for silent myocardial ischaemia. 23 The combination of microalbuminuria and silent ischaemia in patients with asymptomatic diabetes identifies a high-risk subgroup 24 who are likely to benefit from further investigation. 25 No risk factors, including neuropathy, preferentially predicted silent MI (compared with clinical MI). However, the causal association between diabetic autonomic neuropathy and silent MI has been challenged by some authors. 2 Furthermore, the Fremantle Diabetes Study showed no correlation between peripheral sensory neuropathy or other microvascular complications and silent MI. 3 Peripheral neuropathy was also not implicated when type 2 diabetic patients were screened for silent myocardial ischaemia in two other studies. 13, 26 All studies of silent MI have an inherent survival bias, in that to have a detectable silent MI the patient must survive the index event until the time of the surveillance ECG. This may partly explain the intermediate baseline risk profile of those experiencing silent MI and the lower rate of anterior silent MI, as patients at higher risk and those with large anterior MIs may be more likely to present clinically or not survive the event. Despite this potential bias, the risk of future CVD events in the FIELD study was very similar for those experiencing a silent MI and those with a clinical MI.
The high mortality rate after a clinical MI 27, 28 and after revascularization 29, 30 is well documented in patients with type 2 diabetes, but less well after a silent MI. This study shows that total mortality and cardiovascular mortality after silent MI is significantly higher This study did not count non-Q wave infarctions. Criteria for retrospective diagnosis of non-Q wave MI are problematic, with ECG changes that are much less specific. As their MIs were silent, these patients would not have ECGs available from the period of such an event. In contrast, a Q wave infarction is regarded as a more important clinical event and can be adjudicated reliably. The low frequency of surveillance ECGs meant that the exact dates of silent MIs could not be identified, affecting our ability to definitively describe prognosis. There is evidence that Q waves can resolve with time, 33, 34 which could explain why the prevalence of silent MI was lower than in the Fremantle Diabetes Study, which employed yearly ECG screening. 3 Many fatal FIELD cases lacked autopsy, precluding a diagnosis of fatal silent MI. Autonomic neuropathy was not formally tested and as such cannot be excluded as an important risk factor for silent MI. In summary, in this large cohort of 9795 patients with type 2 diabetes, silent MI defined on a resting 12-lead ECG was an important clinical endpoint, identifying a group with intermediate baseline risk and high risk of future CVD events. Treatment with fenofibrate reduced not only the risk of a first MI but also the risk of further CVD events after a silent MI. This study suggests that consideration of ECG screening for silent MI may be warranted in asymptomatic patients with type 2 diabetes to predict future cardiovascular events and to better identify those who might benefit from more aggressive risk screening and management, including fenofibrate therapy. 
